Work

Supplementary Table 2 from Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab

Year: 2023
Type: supplementary-materials
Abstract: Frequency of clinico-pathological characteristics in HER2-positive BC patients according to pSrc classification.
Language: English
Subfield: Oncology
Field: Medicine
Open Access status: gold
OpenAlex ID: W4361811043
Cites:
Cited by:
Related to: 10